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CLINICAL AND TRANSLATIONAL RESEARCH IN PNEUMOCYSTIS 
AND PNEUMOCYSTIS PNEUMONIA 1
HUANG L.*
Summary:
Pneumocystis pneumonia (PcP) remains a significant cause of 
morbidity and mortality in immunocompromised persons, especially 
those with human immunodeficiency virus (HIV) infection. 
Pneumocystis colonization is described increasingly in a wide range 
of immunocompromised and immunocompetent populations and 
associations between Pneumocystis colonization and significant 
pulmonary diseases such as chronic obstructive pulmonary 
disease (COPD) have emerged. This mini-review summarizes 
recent advances in our clinical understanding of Pneumocystis 
and PcP, describes ongoing areas of clinical and translational 
research, and offers recommendations for future clinical research 
from researchers participating in the “First centenary of the 
Pneumocystis discovery”.
KEY WORDS: Pneumocystis, colonization, Pneumocystis pneumonia 
(PcP), human immunodeficiency virus (HIV), acquired immune deficiency 
syndrome (AIDS).
Résumé : LA RECHERCHE CLINIQUE SUR LE PNEUMOCYSTIS ET LA 
PNEUMOCYSTOSE PULMONAIRE
La pneumocystose pulmonaire (PcP) est responsable d’une 
importante morbidité et mortalité chez les personnes 
immunodéprimées, particulièrement celles qui sont porteuses 
du virus de l’immunodéficience humaine (VIH). L’infection par le 
Pneumocystis s’observe de plus en plus, tant dans des populations 
immunodéprimées qu’immunocompétentes, et notamment 
chez des personnes atteintes de broncho-pneumopathies 
chroniques obstructives (BPCO). Cette mise au point recense les 
données récentes qui concernent la clinique de l’infection par 
le Pneumocystis, notamment la PcP, et les recommandations 
et les recherches en cours dans le domaine, telles qu’elles ont 
été présentées lors de la conférence commémorant le premier 
centenaire de la découverte de Pneumocystis.
MOTS-CLÉS : Pneumocystis, infection, pneumocystose pulmonaire (PcP), 
virus de l’immunodéficience humaine (VIH), syndrome de l’immunodéficience 
acquise (SIDA).
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INTRODUCTION
The year 2009 marked the 100
th anniversary of 
the first description of Pneumocystis by Carlos 
Chagas. Over the past 100 years, significant 
advances have been made in our understanding of 
both Pneumocystis and Pneumocystis pneumonia 
(PcP). The preeminence of PcP as a herald of the 
human immunodeficiency virus (HIV) / acquired 
immune deficiency syndrome (AIDS) epidemic and 
as a major cause of HIV-associated morbidity and 
mortality focused attention and resources on this pre-
viously uncommon opportunistic pneumonia. With 
the use of combination antiretroviral therapy to treat 
underlying HIV infection, the incidence of PcP has 
declined, but an appreciation of Pneumocystis colo-
nization in both immunocompromised and immu-
nocompetent populations, and associations between 
Pneumocystis colonization and significant pulmonary 
diseases such as chronic obstructive pulmonary 
disease (COPD), have emerged. This mini-review 
summarizes recent advances in our clinical unders-
tanding of Pneumocystis and PcP, describes ongoing 
areas of clinical and translational research, and offers 
recommendations for future clinical research from 
researchers participating in the “First centenary of the 
Pneumocystis discovery” held in Brussels, Belgium on 
November 5-6, 2009.
EPIDEMIOLOGY OF PCP
PcP is a frequent AIDS-defining diagnosis. At its peak, PcP was an AIDS-defining diagnosis for greater than 20,000 new AIDS cases per year 
in the US (Centers for Diseases Control and Preven-
tion, 1990-1993). Although the incidence of PcP has 
decreased in the current era of combination antiretro-
viral therapy, PcP remains a leading cause of AIDS 
in North American and European cohorts (Mocroft et 
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al., 2009). In the multinational Antiretroviral Therapy 
Cohort Collaboration (ART-CC) established in 2000, 
PcP was the second most frequent AIDS-defining event 
after esophageal candidiasis (Mocroft et al., 2009). 
Therefore, continued efforts to improve our unders-
tanding of both Pneumocystis and PcP are warranted 
(Table I).
PcP is an important cause of HIV-associated pneu-
monia but rates of PcP have decreased. At San Fran-
cisco General Hospital, the Division of Pulmonary 
and Critical Care Medicine has tracked confirmed 
cases of PcP – diagnosed by microscopic visualization 
of characteristic Pneumocystis cysts and/or trophic 
forms obtained from sputum induction or broncho-
scopy – since 1990 (Fig. 1). At its peak in 1992, nearly 
300 cases of HIV-associated PcP were diagnosed at this 
institution (Huang et al., 1995). Today, this number has 
decreased to 20-30 cases per year. Most of these cases 
occurred in persons who were not receiving antire-
troviral therapy or PcP prophylaxis and many were 
actually unaware of their HIV infection at the time 
of presentation (Fei et al., 2009). This experience is 
similar at other institutions, where 23-31 % of reported 
PcP cases occurred in persons who were newly dia-
gnosed with HIV infection at the time of PcP (Fei 
et al., 2009a; Radhi et al., 2008; Walzer et al., 2008). 
Thus, increased efforts to test persons at risk of HIV, to 
engage HIV-infected persons in regular medical care, 
and to initiate and adhere to combination antiretroviral 
therapy and PcP prophylaxis are important strategies 
to decrease the incidence of the disease.
Comprehensive reviews document that HIV-associated 
PcP is reported throughout the world, in varying rates 
(Davis et al., 2007; Fisk et al., 2003). However, data on 
the current rates of PcP in regions of the world that 
bear the greatest burden of HIV are limited. The scar-
city of diagnostic and microbiologic tools to diagnose 
the disease is an important reason for the limited data 
on PcP rates. Thus, those institutions that possess these 
tools offer valuable windows into the epidemiology of 
PcP in low- and middle-income settings. At Mulago 
Hospital in Kampala, Uganda, the frequency of PcP 
among HIV-infected persons hospitalized with sus-
pected pneumonia who have negative sputum acid 
fast bacilli (AFB) smears and undergo bronchoscopy 
has decreased from nearly 40 % of bronchoscopies to 
less than 10 % (Worodria et al., 2003; Worodria et al., 
2010). Yet, the mortality associated with PcP remains 
high. Thus, efforts to improve both diagnostic and 
microbiologic capacity in low- and middle-income 
settings and to establish surveillance networks to track 
PcP cases are important clinical care and epidemio-
logic resources that should be developed.
Although the populations of non-HIV immunosup-
pressed are rising with the increased use of immuno-
suppressive or immunomodulating therapies to treat 
a wide spectrum of medical illnesses, data on the 
frequency of PcP among these populations are limited. 
As such, consensus on optimal diagnostic, therapeutic, 
and preventative strategies lag behind those for HIV-
infected populations. Similar to recommendations for 
tracking PcP in low- and middle-income settings, col-
laborative networks of institutions that care for subs-
tantial numbers of these non-HIV individuals (similar 
to those established for HIV-infected persons) should 
be created.
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Epidemiology
1. What is the current incidence of PcP in HIV-infected populations?
a. What is the incidence in high-income countries, including the US and Western Europe, where access to combination anti-
retroviral therapy is generally widely available?
i. In these countries, which populations continue to develop PcP?
ii. Strategies to identify persons at risk for HIV and PcP need to be refined and preventative measures need 
to be implemented.
b. What is the incidence in low- and middle-income countries, where access to combination antiretroviral therapy is generally 
more limited?
i. In these countries, which populations develop PcP?
ii. Strategies to identify persons at risk for HIV and PcP need to be refined and preventative measures need 
to be implemented.
iii. Efforts to improve diagnostic and microbiologic capacity are needed.
iv. Surveillance networks to track PcP cases should be developed.
2. What is the current incidence of PcP in non-HIV, immunocompromised populations?
a. What is the incidence in populations immunocompromised from “traditional” immunosuppressive agents (e.g., glucocorti-
coid medications) and disease therapies (e.g., therapies for hematologic malignancy and cancer and after hematopoietic stem 
b. What is the incidence in populations immunocompromised from “newer” biologic, immunomodulating agents (e.g., tumor 
necrosis factor-alpha inhibitors)?
c. Surveillance networks to track PcP cases should be developed.
Diagnosis
3. What is the optimum approach to the diagnosis of PcP?
a. Bronchoscopy with bronchoalveolar lavage (BAL)?
b. Sputum induction (SI), followed by BAL, if SI is negative?
4. Is there a role for non-invasive tests in PcP diagnosis?
a. Oropharyngeal washing (OPW): Which specimen? Which assay? Which protocol?
b. Plasma s-adenosylmethionine?
c. (1-3)-beta-D-glucan?
d. Is the diagnostic accuracy different in non-HIV populations (lower Pneumocystis burden)?
Treatment
5. New drugs to treat and prevent PcP are needed.
6. What is the optimum second-line treatment for PcP?
a. Prospective, randomized clinical trials are needed.
7. Does TMP-SMX drug resistance exist?
a. What is (are) the mechanisms?
i. Dihydropteroate synthase (DHPS) gene mutations?
ii. Dihydrofolate reductase (DHFR) gene mutations?
iii. Sub-therapeutic trimethoprim or sulfamethoxazole drug levels?
iv. Host factors?
Outcome and Intensive care
8. What is the optimal timing for initiation of ART in HIV-associated PcP?
a. In Intensive care unit (ICU)?
b. Outside of the ICU?
9. What is the incidence of PcP-IRIS?
a. What are the risk factors?
b. Can PcP-IRIS be prevented (prophylaxis)?
Pneumocystis colonization
10. What are the implications of Pneumocystis colonization for the colonized individual?
a. COPD?
b. Other pulmonary diseases?
11. Can persons colonized with Pneumocystis transmit infection to others?
a. Risk factors for transmission – source, environment, contact.
Table I. – Conference Recommendations for future directions in clinical and translational research in Pneumocystis and Pneumocystis 
pneumonia.
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PCP DIAGNOSIS
Classically, PcP presents with fevers, non-produc-tive cough, and progressive shortness of breath. Chest radiograph demonstrates bilateral, sym-
metric reticular (interstitial) or granular opacities. Tra-
ditionally, bronchoscopy with bronchoalveolar lavage 
(BAL) is regarded as the gold standard procedure to 
diagnose PcP in HIV-infected persons with diagnostic 
sensitivity ≥ 98 % reported (Huang et al., 1995). An 
early study reported a lower number of Pneumocystis 
organisms and a lower sensitivity of BAL for PcP in 
non-HIV immunocompromised persons compared 
to HIV-infected persons (Limper et al., 1989). More 
recently, BAL combined with sensitive laboratory tech-
niques (e.g., immunofluoresence testing, polymerase 
chain reaction, PCR) has been reported as sensitive to 
diagnose PcP in these non-HIV immunocompromised 
populations (Azoulay et al., 2009). Since Pneumocystis 
DNA can be detected by PCR assay in the absence of 
clinical or microbiological pneumonia (Davis et al., 
2007), the increased sensitivity of PCR-based assays 
may be offset by a decreased specificity for PcP.
Pneumocystis cannot be cultured. Historically, the 
diagnosis of PcP has involved an invasive pulmonary 
procedure (i.e., bronchoscopy) to obtain specimens 
combined with a basic laboratory test (i.e., micro-
scopic examination of stained respiratory specimens) 
to visualize the cysts and/or tropic forms. However, 
bronchoscopy requires specialized personnel, rooms, 
and equipment, and it is also expensive and carries 
an associated risk of complications. Thus, broncho-
scopy is limited in its availability throughout many 
areas of the world that are burdened with HIV/AIDS. 
Laboratory advances (e.g., PCR), however, have revo-
lutionized the diagnosis of many infectious diseases 
and PCR assays for P. jirovecii have been developed. 
These factors led researchers to examine whether the 
use of an advanced laboratory test (e.g., PCR) could be 
combined with a non-invasive pulmonary procedure 
to effectively diagnose PcP.
Oral or oropharyngeal (i.e., gargle) wash specimens 
combined with PCR assays have been examined as 
non-invasive tests to diagnose PcP. Two studies from 
San Francisco General Hospital that tested three dif-
ferent PCR-based assays found a diagnostic sensitivity 
of OPW up to 88 % and a specificity up to 90 % (de 
Oliveira et al., 2007; Larsen et al., 2004). Procedural 
factors such as collecting the OPW specimen within 
one day of PcP treatment initiation and having the 
patient cough vigorously prior to specimen collection 
may increase the sensitivity of the procedure. Studies 
are being conducted to validate these findings in both 
high- and low-income settings.
Blood-based assays have also been studied for dia-
gnosis of PcP. A series of studies from New York 
indicate that plasma S-adenosylmethionine (SAM) 
levels could be used to distinguish between persons 
with PcP and those with non-PcP pneumonia and 
healthy controls (Skelly et al., 2003; Skelly et al., 2008). 
More recently, serum (1-3)-beta-D-glucan has shown 
promise as a test for PcP. Studies from 2009 reported 
that serum (1-3)-beta-D-glucan had a sensitivity of 
100 % and a specificity of 96.4 % (using a cutoff of 
100 pg/mL), that the assay may be more useful for PcP 
diagnosis than for monitoring response to treatment, 
that levels differ between patients with PcP and those 
who are PcP-negative but colonized with Pneumocystis 
jirovecii, and that the detection rate is lower in non-
HIV PcP patients than in HIV-associated PcP patients 
(Desmet et al., 2009; Nakamura et al., 2009; Shimizu et 
al., 2009; Watanabe et al., 2009). Studies to determine 
which non-invasive test has the best performance 
characteristics in different immunocompromised popu-
lations at risk for PcP should be done.
PCP TREATMENT AND PREVENTION 
AND PUTATIVE TRIMETHOPRIM-
SULFAMETHOXAZOLE DRUG RESISTANCE
Trimethoprim-sulfamethoxazole is the recom-mended first-line treatment for PcP in HIV-infected patients with mild, moderate, and 
severe PcP and also in non-HIV patients. Alternative 
regimens include intravenous pentamidine, clinda-
mycin plus primaquine, trimethoprim plus dapsone, 
and atovaquone suspension. Adjunctive corticosteroids 
are recommended for patients with moderate to severe 
PcP as demonstrated by an arterial oxygen tension 
(PaO2) less than 70 mm Hg or an alveolar-arterial 
oxygen gradient (A-a O2) greater than 35 mm Hg. 
In HIV-infected patients, the recommended duration 
of treatment is 21 days while it is usually 14 days in 
non-HIV patients. However, a substantial proportion 
of individuals cannot complete a full course of tri-
methoprim-sulfamethoxazole due to treatment-limi-
ting toxicity or are switched to an alternate treatment 
regimen due to perceived treatment failure (Fisk et 
al., 2009). Although there are only limited data from 
prospective, randomized clinical trials comparing 
second-line PcP treatments, a tri-center observational 
study and a systematic review suggest that the combi-
nation of clindamycin plus primaquine is an effective 
alternative to intravenous pentamidine as second-line 
PcP treatment (Benfield et al., 2008; Helweg-Larsen 
et al., 2009). The development of new PcP treatment 
options and prospective, randomized controlled trials 
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comparing second-line PcP treatments are both impor-
tant needs.
Trimethoprim-sulfamethoxazole is also the recom-
mended first-line prevention for primary and secon-
dary prophylaxis against PcP. However, the wides-
pread use of this medication for PcP prophylaxis has 
been associated with increases in trimethoprim-sulfa-
methoxazole-resistant bacteria and has raised concerns 
over potential trimethoprim-sulfamethoxazole drug 
resistance in P. jirovecii. Trimethoprim-sulfamethoxa-
zole drug resistance might also result in resistance to 
trimethoprim plus dapsone (a sulfone), thereby further 
limiting the therapeutic options available to treat PcP. 
The inability to culture P. jirovecii has hindered efforts 
to document drug-resistance in Pneumocystis but 
researchers have explored this question by examining 
genetic mutations within the dihydrofolate reductase 
(DHFR) and dihydropteroate synthase (DHPS) genes, 
the enzymatic targets of trimethoprim and sulfa (sul-
famethoxazole and dapsone) medications, respectively 
(Huang et al., 2004). In other micro-organisms, DHFR 
and DHPS mutations have been shown to cause drug 
resistance. Although DHFR mutations are infrequently 
found, non-synonymous DHPS mutations are found in 
up to 81 % of HIV-infected patients with PcP and the 
use of sulfa medications for PcP prophylaxis is strongly 
associated with the presence of these mutations 
(Crothers et al., 2005; Huang et al., 2000). DHPS muta-
tions continue to be reported worldwide and there 
are geographic differences in the observed frequency 
of mutations (Alvarez-Martinez et al., 2008; Beard et 
al., 2000; Crothers et al., 2005; Esteves et al., 2008; 
Huang et al., 2000; Magne et al., 1989; Rabodonirina 
et al., 2006; Wissmann et al., 2006). Furthermore, the 
presence of DHPS mutations has been associated with 
increased mortality in one study and increased risk of 
trimethoprim-sulfamethoxazole PcP treatment failure 
in a second study, although other studies have failed 
to find these associations and instead have reported 
that risk factors such as low serum albumin and early 
ICU admission were stronger predictors of PcP morta-
lity (Crothers et al., 2005; Helweg-Larsen et al., 1999; 
Kazanjian et al., 2000).
At present, there exists a seeming paradox regarding 
the clinical significance of DHPS mutations. Studies 
consistently report that the majority of patients with 
PcP and DHPS mutations who are treated with tri-
methoprim-sulfamethoxazole respond to this treatment 
(Crothers et al., 2005; Helweg-Larsen et al., 1999; 
Kazanjian et al., 2000; Navin et al., 2001). However, 
patients with DHPS mutations who are treated with 
trimethoprim-sulfamethoxazole tend to have worse 
outcomes compared to those with wild-type DHPS 
who are treated with trimethoprim-sulfamethoxazole 
and those with DHPS mutations who are treated with 
a non-sulfa-based regimen (Crothers et al., 2005). The 
precise explanation for these observations remains a 
focus of current investigation.
PCP MORTALITY AND INTENSIVE CARE
Despite differences in geography and demo-graphic characteristics, in-hospital mortality among HIV-infected patients with PcP is 
similar (ranging from 10.3 to 13.5 %) in different 
cohort studies from Los Angeles, London, and San 
Francisco (Fei et al., 2009b; Radhi et al., 2008; Walzer 
et al., 2008). Each of these studies also reported on 
predictors of mortality. In the Los Angeles study of 262 
HIV-infected patients diagnosed with PcP from January 
2000 through December 2003, need for mechanical 
ventilation, development of a pneumothorax, and 
low serum albumin were independent predictors of 
increased mortality (Radhi et al., 2008). In the London 
study of 494 consecutive HIV-infected patients with 
547 episodes of laboratory-confirmed PcP from June 
1985 through June 2006, increasing patient age, sub-
sequent episode of PcP, low hemoglobin level, low 
partial pressure of oxygen breathing room air, pre-
sence of medical comorbidity, and pulmonary Kaposi 
sarcoma were independent predictors associated with 
increased mortality (Walzer et al., 2008). Mortality 
was comparable during the periods from June 1985 
through December 1989, January 1990 through June 
1996, and July 1996 through June 2006 (p = 0.14). 
Finally, in the San Francisco study of 451 consecutive 
HIV-infected patients diagnosed with 524 episodes 
of microscopically-confirmed PcP from January 1997 
through December 2006, increasing patient age, recent 
injection drug use, increased total bilirubin, decreased 
serum albumin, and increased alveolar-arterial oxygen 
gradient were independent predictors of increased 
mortality (Fei et al., 2009b). Using these five predic-
tors, a six-point PcP mortality prediction rule was 
derived that stratified patients according to increasing 
risk of mortality: score 0-1, 4 % mortality; score 2-3, 
12 % mortality; and score 4-5, 48 % mortality. Studies 
are being conducted to validate these single-institution 
findings in other cohorts.
A few institutions have tracked PcP in HIV-infected 
patients requiring critical care in the Intensive Care 
Unit (ICU). Among these institutions, a study from San 
Francisco General Hospital in the current combination 
antiretroviral therapy era reported that critically ill HIV-
infected patients with PcP who received combination 
antiretroviral therapy had a significantly lower mortality 
compared to patients who did not receive antiretroviral 
therapy (Morris et al., 2003). The use of combination 
antiretroviral therapy was an independent predictor 
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that was associated with lower mortality (odds ratio, 
OR = 0.14; 95 % confidence interval, CI = 0.02-0.84; 
p = 0.03). A study from London, however, failed to 
find a mortality difference associated with combina-
tion antiretroviral therapy (Miller et al., 2006). In this 
study, mortality improved from 71 % before mid-1996 
to 34 % after mid-1996 (p = 0.008). This improvement 
in mortality was ascribed to general improvements 
in care as no patients were started on combination 
antiretroviral therapy. In the absence of data from ran-
domized clinical trials, the pros and cons of initiating 
antiretroviral therapy in critically ill HIV-infected ICU 
patients have been debated. Recently, the National 
Institutes of Health (NIH)-funded AIDS Clinical Trials 
Group (ACTG) published its results of a prospective, 
multicenter randomized clinical trial of HIV-infected 
non-ICU inpatients hospitalized with an acute opportu-
nistic infection (Zolopa et al., 2009). Overall, 282 sub-
jects were enrolled and 63 % had PcP. The study found 
no difference in their primary endpoint. However, 
subjects randomized to the early antiretroviral therapy 
arm had fewer AIDS progressions/deaths (OR = 0.51, 
95 % CI = 0.27-0.94, p = 0.035) and a longer time 
to AIDS progression/death (stratified Hazard Ratio, 
HR = 0.53, 95 % CI = 0.30-0.92). Importantly, there was 
no increase in adverse events in subjects randomized 
to early antiretroviral therapy in this study but cases of 
severe immune reconstitution inflammatory syndrome 
(IRIS, also called immune reconstitution syndrome, 
IRS, and immune reconstitution disease, IRD) resulting 
in respiratory failure and requiring invasive mecha-
nical ventilation have been reported and serve as a 
cautionary note (Jagannathan et al., 2009). Whether 
the ACTG results from hospitalized but non-critically 
ill patients can be extrapolated into the ICU, where 
patients are often receiving mechanical ventilation 
and have renal and/or hepatic insufficiency, is an 
important but largely unanswered question (Huang 
et al., 2006). 
PNEUMOCYSTIS COLONIZATION 
AND POTENTIAL PERSON-TO-PERSON 
TRANSMISSION
The presence of Pneumocystis organisms or P. jirovecii DNA detected in the absence of PcP has been termed Pneumocystis colonization 
(also called carriage and sub-clinical infection). Pneu-
mocystis colonization has been increasingly reported 
and documented to occur in infants and children, pre-
gnant women, immunocompetent adults with under-
lying pulmonary disease, non-HIV immunocompro-
mised individuals, and HIV-infected persons (Morris et 
al., 2008). For example, in one study of 58 infants < 1 
year of age who died, Pneumocystis colonization was 
detected in 100 % (Beard et al., 2005). HIV-infected 
inpatients hospitalized with non-PcP pneumonia also 
appear to have a high prevalence of Pneumocystis 
colonization, with one study reporting a prevalence 
of 68 % (Davis et al., 2008). 
Colonization with Pneumocystis has also been asso-
ciated with airways obstruction and chronic obstruc-
tive pulmonary disease (COPD) and possibly with 
other pulmonary diseases as well (Vidal et al., 2006). 
In one study, Pneumocystis colonization was detected 
in 36.7 % of HIV-negative patients with very severe 
COPD (Global Health Initiative on Obstructive Lung 
Disease [GOLD] Stage IV) compared with 5.3 % of 
smokers with normal lung function or less severe 
COPD (GOLD Stages 0, I, II, and III) (p = 0.004) and 
with 9.1 % of control subjects (p = 0.007) (Morris et 
al., 2004). Pneumocystis colonized subjects exhibited 
more severe airway obstruction (median FEV1 = 21 % 
predicted vs 62 % predicted in non-colonized subjects, 
p = 0.006). In a second study, patients colonized with 
Pneumocystis had higher proinflammatory cytokine 
levels than did those patients without evidence of 
Pneumocystis colonization (Calderon et al., 2007). 
Finally, HIV-infected outpatients who were colonized 
with Pneumocystis had worse airway obstruction and 
higher sputum matrix metalloprotease-12 levels, sug-
gesting that Pneumocystis colonization may be impor-
tant in HIV-associated COPD (Morris et al., 2009). 
Studies to further evaluate the role of Pneumocystis 
colonization in the development and the progression 
of HIV-associated COPD are ongoing.
Although the clinical significance of Pneumocystis 
colonization remains to be elucidated completely, 
important insights can be gained from studies in labo-
ratory animals. An animal model has been developed 
to study Pneumocystis colonization in immunocom-
petent and simian immunodeficiency virus (SIV)-
infected cynomolgus macaques and the potential role 
of Pneumocystis colonization on COPD (Kling et al., 
2009). Animal studies have also been used to study 
disease transmission. These studies demonstrate that 
animals are a reservoir for the specific Pneumocystis 
species that affects them, that animals carrying Pneu-
mocystis develop PcP after being immunosuppressed 
(reactivation), and that immunocompromised Pneu-
mocystis-free animals develop PcP after exposure to 
not only immunocompromised animals infected with 
Pneumocystis but also immunocompetent animals that 
are colonized with Pneumocystis. Animal studies also 
demonstrate that animal-to-animal transmission occurs 
and occurs via an airborne route.
Person-to-person transmission of Pneumocystis via an 
airborne (aerosol) route has been suggested. However, 
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a precise understanding of the factors involved in 
disease transmission remains unclear and there are no 
universal recommendations for the respiratory isolation 
of persons with active PcP. Even if such recommen-
dations became standard practice, disease transmis-
sion could hypothetically occur via persons who are 
colonized with Pneumocystis as is the case in animal 
studies. Molecular epidemiology and serology studies 
to examine potential person-to-person transmission 
are ongoing.
CONCLUSIONS
Over the past 100 years, significant advances have been made in our understanding of both Pneumocystis and Pneumocystis pneumonia 
(PcP). This mini-review described recent advances in 
our understanding of Pneumocystis and PcP, ongoing 
areas of clinical and translational research, and offered 
recommendations for future clinical research from 
researchers participating in the First centenary com-
memorative Conference on the discovery of Pneumo-
cystis. The attendees of the conference sincerely hope 
that the next 100 years bring continued advances in 
our understanding of the organism and the disease.
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